Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma

Journal of Clinical Oncology

Volumn 21, Issue 20, 2003, Pages 3853-3858

  Cheung, Irene Y ^a   Lo Piccolo, M Serena ^a   Kushner, Brian H ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GANGLIOSIDE GD2; GANGLIOSIDE GD2 ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; (N ACETYLNEURAMINYL) GALACTOSYLGLUCOSYLCERAMIDE N ACETYLGALACTOSAMINYLTRANSFERASE; (N-ACETYLNEURAMINYL)-GALACTOSYLGLUCOSYLCERAMIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; 3F8 ANTIBODY; IMMUNOGLOBULIN G; MESSENGER RNA; MONOCLONAL ANTIBODY; N ACETYLGALACTOSAMINYLTRANSFERASE; RECOMBINANT PROTEIN; TUMOR MARKER;

ARTICLE; BIOLOGICAL THERAPY; BONE MARROW DISEASE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER STAGING; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BONE MARROW; BONE MARROW CANCER; ENZYMOLOGY; INFANT;

ANTIBODIES, MONOCLONAL; BONE MARROW; BONE MARROW NEOPLASMS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN G; INFANT; N-ACETYLGALACTOSAMINYLTRANSFERASES; NEOPLASM, RESIDUAL; NEUROBLASTOMA; PROGNOSIS; RECOMBINANT PROTEINS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 0142023880     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.11.077     Document Type: Article

References (29)

1. Ladenstein R, Philip T, Lasset C, et al: Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16:953-965, 1998
2. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 341:1165-1173, 1999
3. Cheung NK, Kushner BH, Cheung IY, et al: Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 16:3053-3060, 1998
4. Frost JD, Hank JA, Reaman GH, et al: A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma. Cancer 80:317-333, 1997
5. Yu AL, Batova A, Alvarado C, et al: Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma: A POG phase II study. Proc Am Soc Clin Oncol 16:1846, 1997
6. Ozkaynak MF, Sondel PM, Krailo MD, et al: Phase I study of chimeric human/murine antiganglioside GD2 monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma inmmediately after hematopoietic stem-cell transplantation: A Children's Cancer Group Study. J Clin Oncol 18:4077-4085, 2000
7. D2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 19:4189-4194, 2001
8. Kushner BH, Cheung NK: GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 73:1936-1941, 1989
9. Furukawa K, Soejima H, Niikawa N, et al: Genomic organization and chromosomal assignment of the human β1, 4-N-acetylgalactosaminyltransferase gene. J Biol Chem 271:20836-20844, 1996
10. Kramer K, Gerald W, Kushner BH, et al: Disialoganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Clin Cancer Res 4:2135-2139, 1998
11. Cheung IY, Cheung NKV: Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin Cancer Res 7:1698-1705, 2001
12. Lo Piccolo MS, Cheung NKV, Cheung IY: GD2 Synthase: A new molecular marker for detecting neuroblastoma. Cancer 92:924-931, 2001
13. Hoon DSB, Kuo CT, Wen S, et al: Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow. Am J Pathol 159:493-500, 2001
14. Cheung IY, Lo Piccolo MS, Collins N, et al: Quantitation of GD2 synthase mRNA by real-time reverse transcription-PCR: Utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8. Cancer 94:3042-3048, 2002
15. Cheung IY, Lo Piccolo MS, Kushner BH, et al: Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: Clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol 21:1087-1093, 2003
16. Brodeur G, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 11:1466-1477, 1993
17. Cheung NK, Cheung IY, Canete A, et al: Antibody response to murine anti-GD2 monoclonal antibodies: Correlation with patient survival. Cancer Res 54:2228-2233, 1994
18. Cheung NK, Heller G, Kushner BH, et al: Detection of metastatic neuroblastoma in bone marrow: When is routine marrow histology insensitive? J Clin Oncol 15:2807-2817, 1997
19. Cheung IY, Cheung NKV: Molecular detection of GAGE expression in peripheral blood and bone marrow: Utility as a tumor marker for neuroblastoma. Clin Cancer Res 3:821-826, 1997
20. Ross AA: Minimal residual disease in solid tumor malignancies: A review. J Hematother 7:9-18, 1998
21. Seeger RC, Reynolds CP, Gallego R, et al: Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: A Children's Cancer Group study. J Clin Oncol 18:4067-4076, 2000
22. Cheung IY, Chi SN, Cheung NKV: Prognostic significance of GAGE detection in bone marrows on survival of patients with metastatic neuroblastoma. Med Pediatr Oncol 35:632-634, 2000
23. Burchill SA, Lewis IJ, Abrams KR, et al: Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol 19:1795-1801, 2001
24. Pongers-Willemse MJ, Verhagen OJHM, Tibbe GJM, et al: Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 12:2006-2014, 1998
25. Kwan E, Norris MD, Zhu L, et al: Simultaneous detection and quantification of minimal residual disease in childhood acute lymphoblastic leukaemia using real-time polymerase chain reaction. Br J Haematol 109:430-434, 2000
26. Verhagen OJ, Willemse MJ, Breunis WB, et al: Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 14:1426-1435, 2000
27. Gaynon PS, Desai AA, Bostrom BC, et al: Early response to therapy and outcome in childhood acute lymphoblastic leukemia: A review. Cancer 80:1717-1726, 1997
28. Gruhn B, Hongeng S, Yi H, et al: Minimal residual disease after intensive induction therapy in children acute lymphoblastic leukemia predicts outcome. Leukemia 12:675-681, 1998
29. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al: Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352:1731-1738, 1998